India could soon get a lot thinner - at least in theory. On Friday, the patent on semaglutide - the molecule behind Danish drugmaker Novo Nordisk's blockbuster weight-loss drugs Wegovy and Ozempic - expires in the country. This will allow domestic pharmaceutical companies to release cheaper copies or generics, triggering a rush of competition that could slash prices by more than half and rapidly expand access for people in India, and eventually in other countries too. Investment bank Jefferies has called it a potential 'magic-pill moment' for India, predicting the semaglutide market could eventually reach $1bn domestically with the right pricing and uptake.
Analysts expect around 50 branded semaglutide generics to enter the market within months - a familiar pattern in India's fiercely competitive pharmaceutical industry. Current monthly treatment costs are steep, with Ozempic selling for 8,800 - 11,000 rupees ($95-$119) and Wegovy costing 10,000-16,000 rupees ($108-$173). With generics, prices could drop to roughly 3,000-5,000 rupees ($36-54).
The surge reflects a broader health shift, as India's pharmaceutical industry, worth about $60bn, is expected to double by 2030. With more than 77 million people suffering from type-2 diabetes in India, the introduction of affordable GLP-1 drugs could provide a vital new tool in combating diabetes and obesity. However, doctors express concern about ensuring the quality of these medications and the potential for misuse as prices fall.
As cheaper generics become available, it will be crucial for regulators to balance accessibility with oversight, ensuring these transformative drugs are used safely and effectively in the fight against global obesity.
Analysts expect around 50 branded semaglutide generics to enter the market within months - a familiar pattern in India's fiercely competitive pharmaceutical industry. Current monthly treatment costs are steep, with Ozempic selling for 8,800 - 11,000 rupees ($95-$119) and Wegovy costing 10,000-16,000 rupees ($108-$173). With generics, prices could drop to roughly 3,000-5,000 rupees ($36-54).
The surge reflects a broader health shift, as India's pharmaceutical industry, worth about $60bn, is expected to double by 2030. With more than 77 million people suffering from type-2 diabetes in India, the introduction of affordable GLP-1 drugs could provide a vital new tool in combating diabetes and obesity. However, doctors express concern about ensuring the quality of these medications and the potential for misuse as prices fall.
As cheaper generics become available, it will be crucial for regulators to balance accessibility with oversight, ensuring these transformative drugs are used safely and effectively in the fight against global obesity.
